Q&As

Q&As

These Q&As seek to briefly address common questions faced when dealing with Life Sciences matters.

The Q&As supplement and link to other more detailed content within Lexis®+ UK, but are intentionally short. It is anticipated that a brief Q&A will be most helpful when you need a quick overview of an issue and its likely impact. This might arise, for example, for lawyers needing to provide advice, provide business development or training at short notice. The Q&A content on Lexis®+ UK Practical Guidance is date stamped. This date is the publish date and

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

MedTech Europe outlines how industry can drive healthcare Decarbonisation

MedTech Europe commissioned the report 'Decarbonising Healthcare: How a Competitive MedTech Industry Can Contribute' from the Boston Consulting Group (BCG), with contributions from member companies and a dedicated Steering Committee. The report outlines how the European medical technology (MedTech) sector can support healthcare decarbonisation while enhancing competitiveness, in alignment with the EU’s legally binding target of net zero greenhouse gas emissions by 2050 under the European Climate Law.

Data (Use and Access) Bill to receive Royal Assent on 19 June 2025

The Data (Use and Access) Bill (DUA) is set to receive Royal Assent and become an Act of Parliament on Thursday 19 June 2025. This follows its parliamentary review being finalised on 11 June 2025 and marks the culmination of nearly eight months of parliamentary procedure. Under section 139 of the DUA, most provisions will come into force as and when the Secretary of State appoints regulations. However, a limited number of provisions will come into force upon Royal Assent. This includes section 78, which relates to reasonable and proportionate searches for data subject access requests. It also includes sections 126–128 on the retention of biometric data, and schedule 16 on the grant of energy smart meter communication licences.

CTSI calls for urgent regulation of cosmetic procedures amid safety concerns

The Chartered Trading Standards Institute (CTSI) has issued a warning about unregulated aesthetic procedures and called for immediate regulatory reform. The institute identified widespread unsafe practices including procedures being performed in pop-up shops and public toilets, with particular concerns about unregulated fat dissolving injections. Following a death in September 2024 linked to a Brazilian Butt Lift procedure, CTSI is advocating for a national licensing scheme, establishment of a ministerial task force, extension of underage legislation across the UK and removal of unsafe products from online marketplaces. The institute highlighted that most injectable aesthetic services currently operate without regulatory oversight.

DHSC launches 10 Year Health Plan to cut trial delays and expand public access via NHS App

The Department of Health and Social Care, alongside Health and Social Care Secretary Wes Streeting MP, has unveiled the government’s 10 Year Health Plan to overhaul the UK’s clinical trial system. The plan will enable millions of people to access and enrol in clinical trials through the National Institute for Health and Care Research (NIHR) Be Part of Research service via the NHS App, which will eventually include automated matching based on personal health data. The initiative includes a nationwide recruitment campaign, prioritisation of funding for high-performing NHS trusts, and public reporting to enhance transparency and accountability.